And clinical trials of linsitinib showed a prolonged overall survival of in advanced high IGF-1R expression solid tumors (including lung cancer, melanoma, pancreatic cancer, and gastrointestinal stromal tumors) (Jones et al., 2015; Puzanov et al., 2015; Leighl et al., 2017; von Mehren et al., 2020). Here, IGF1R is linked to pancreatic neoplasm.